Addressing an Unmet Need in Hyperuricemia

Hyperuricemia, or elevated levels of uric acid in the blood, results from either overproduction or insufficient excretion of urate, or often a combination of the two. Humans lack urate oxidase, an enzyme that degrades uric acid in other animals. Hyperuricemia can be a predisposing condition for gout and kidney stones, and is also intricately linked with various metabolic disorders, including hypertension, chronic kidney disease, or CKD, glucose intolerance, dyslipidemia, insulin resistance and obesity.

Gout is a kind of arthritis caused by excess uric acid in the blood. When uric acid levels in the blood are too high, hard crystals may form in the joints which activate an inflammatory response from the body, resulting in attacks of sudden burning pain, stiffness, and swelling. These attacks can recur unless gout is treated. Over time, they can harm joints, tendons, and other tissues.

Hyperuricemic and gout patients with renal impairment are more challenging to manage due to limitations of existing therapies. These limitations include poor tolerability, reduced efficacy, dose restriction and contraindications to currently available therapies. Co-morbidities are also common in CKD patients and may also limit urate lowering therapeutic options. Accordingly, there is a significant unmet need for a safe and effective therapy that can be used in patients with CKD.